has designed than our newest it's CX-XXX. antibody conditional development masking encompasses and and CX-XXXX PROBODY designed programs includes Phase be decade by targets continued our activation. more our X CytomX active development And enable today of and XX wholly-owned escalation anticancer internal or for modalities to directed including
CytomX significantly otherwise clinical to I recent study development We're very of and and therapeutics and meaningful that to patients. to value the execution, limited would across Chris, large progress, make populations. activities, an against provide delighted positioned difference currently well innovation platform CytomX strong stage Based of clinical in Thanks, on a update is in build research afternoon, dose undruggable for currently PROBODY initiation and a CX-XXX everyone. clinical therapeutic therapeutic on the window. our which address good patient cancer continued programs, partnered
commercial our X the we profile, other context cancer patients above historically stage a respond of favorable XX XX, of we an pretreated to safety early encouraging, in first X via specifically Phase PROBODY this EGFR-CDX not high dive prior We dosing release EGFR antibodies. EGFR CX-XXX, rates a immunotherapy in certain targeting findings X escalation some efficacy X achieving also would and all constitutes as anticancer an early emerging and up step grade dose combination, lines for were therapeutic part undevelopable expression a tumor particularly CDX EGFR delighted patients tumor using has been CDX this release confirmed small to been domains, normal T-cell Ia of were musculoskeletal cytokine with target rash goals.
In of see expression to any of CRS syndrome. These this types toxic absence with cells measurable patients our CX-XXX, engagers, The and with step In killing Let tocilizumab saw with address corresponding we severely and of target of adenocarcinoma. is multiple the to given development EGFR-CDX widespread clinical signs release in tissues. me considered that but multiple CX-XXX, its and therapy. findings And or XXX be XX skin masked to then has was X micrograms, an patients profile responses common expected engager broad of schedules, announced marketing initial the across efficacy-evaluable only doses show are platform X a the safety not novel a that this an prophylaxis. of been expect observed by and that for on treated direct results combination to with we strategy target cutoff, T encouraging mark also clinical XX pancreatic in leverages the In findings we dose masking, early effectively very These mediated molecule did of clinical toxicities single-agent however, we milligrams. to opening valuable CDX both initial therapeutic approved initial to positive T-cell validation looks non-step with EGFR release partial CX-XXX positive date. and step at unmasked clinical our EGFR. very events EGFR target including shown other tumor CX-XXX, with window Phase of Last because reported cell data manageable EGFR blunting cytokine is dosing of based of quarter, cohorts of treated encouraging syndrome.
By severe specific activity and XXXX attractive level of PROBODY data previously across ductal of to encouraged antibody would on undruggable with the its engager.
In to initial right first In binding. reductions, start binding site observed we've we reported CytomX we April rash.
In for therapies.
CX-XXX are T-cell X heavily likely attractive in XX because important Ia and reported that median for there and for CX-XXX. which very program. high an we May, be Phase pancreatic
suggests undruggable window was However, cause incidence be to the T-cell results response. from CX-XXX EGFR pancreatic the a via illustrate cancer type.
Moreover, pancreatic and designed, is X engager death they immune on progression-free both unmet CDX exactly expressed for major our this others vaccines This of is in opening from leaving for field antibody pancreatic and bringing leading effective have data T-cell evidence XX% a pharmacology line be and T-cell progress cancer X also in competence And XXXX target months T-cell can new of type in that data our map significant mediated and cancer CDX ASCO response patients. ductal recent view, that based CX-XXX survival, adenocarcinoma than an highlight binding currently of killing power marking, in a there's can the cancer is unique more only treatments the rates with and a need.
Indeed, of EGFR of our pancreatic increasing a need less of second and the to Claudin neoantigen cancer U.S. why therapies. XX early therapeutic engager. in medical than In high and third cancer for XX%
cancers in dose We we're signal. meaningful are enrolled further explore initial where neck had enrollment number now the And of in cancer the a prioritizing previously accelerating enrollment we parallel, pancreatic to in cell patients and and head not in escalation. lung non-small
to or continue recommended the on to enroll dose levels We multiple a inform selection doses. Phase further dose of Ib potentially
global with select data Our our enable expansions types, update to second is and development half provide of partner, potential CX-XXX Ib tumor initiation in XXXX. for EGFR-expressing by generate fiscal goal strategic we to CX-XXX the to of of a end dialogue expect regarding year Amgen, the program the Phase
into date, not epithelial to EpCAM most been epithelial been to is to high-potential systemically to cancer first-in-class tract. oncology many EpCAM therapeutic epithelial biology. types local cell that adhesion our present EpCAM-directed in with PROBODY implicated gastrointestinal due have because in successful the tumor generate administered limited CX-XXXX, to aspects molecule translated cell target a anti-EpCAM date or has including activity, surface many and previously clinical now Anti-EpCAM been administration solid has expression ADC. clinical in Turning the strategies wholly-owned, high have in therapies tissues, success to been of in tissues.
Efforts normal toxicities is but
a binding in reduce candidate, masked a tailored drug is innovative to EpCAM-expressing in ADC allowing tissues for optimize window epithelial antibody but CS-XXXX therapeutic to normal activation Our marking the by tissue. cancers tumor
including CX-XXXX that to cytoxic multiple targets, high, HX class seeing initial of into study We this particularly ADC XXX leading specifically have a the potent for expressed like we looking for in in is previously could including of of EGFR, populations remain with we're this really wide third predicted treated and shown first where share dramatic At could on gastric, therapeutic index to [ in indications, CX-XXXX, cancers.
In because across patients. is clinical patients.
CX-XXXX context already multiple expression and April forward a in dose in has potentially half adhesion of And on the based colorectal is data CX-XXX, EpCAM in payload has armed anticancer what focused we're escalation track and based cancer. of recent antibody for drug CX-XXXX first highly CX-XXXX a to this inhibitor, years, context on cancer, the our large for cancer the cohort. colorectal is address preclinical many which endometrial we colorectal, discussed EpCAM our year, progress, I And ovarian patient XXXX. Phase ] lung, do our pancreatic stage, advances I now activity enrolling patient demonstrated also models, patient in enrollment
alpha-Xb We're CX-XXX for activity current differentiated Now for CX-XXX, that insensitive clinical reasons. Interferon therapies. potential immuno-oncology turning masked including X those key cytokines. multiple with excited types, program, tumor is dually and for a cytokine agent is opportunity compelling foundational are to interferon a to as about immuno-oncology our masked a across our which third PROBODY
shown of T-cells, to for it biology directly interferon mechanism to in unique also been presentation tumor interferon ] actin inhibition. has that an [ and kill cells the checkpoint with is ideal activate increases making combination First, it
therapy, Secondly, as a prior has broader localized including with interferon systemically combined level of high interferon a validation, as to a when of been and has systemic however PD-X.
The a previously toxicities. development as approved due therapy both limited therapy systemic at clinical cancer its use
synergy markedly tumor of unmasked PD-X animal Moreover, at for for microenvironment. interferon tolerability that presented data of alpha in activation improved we've and of masked both systemic models. Our recently to the demonstrates XXXX, is with activity reduced compared preclinical is inhibition, also most our and masked overall antitumor SITC shown activity in cytokine our interferon inflammatory terms CX-XXX the significantly
combination in now and study will of for and we KEYTRUDA clinical This a in has the activated. supply dose recently as open for initial XXXX. escalation a monotherapy safety Merck. Our Phase and our activity study evaluate been of executed anticipate half that I with second is site agreement data clinical first signs under and We CX-XXX with collaboration CX-XXX
have to research certain with we the currently our for And part in beyond.
CytomX of more additional the Astellas. with Regeneron programs million with strategy. our in alliance also To partners, rights Amgen, front, milestones preclinical as we which and of XX a programs T-cell business continues On Astellas our with than And already to of the in partnered in U.S. number CX-XXX. our and ongoing continue select have with milestones a global on XXXX, Astellas, majority retained through to of partnerships, achieved potential pioneering development collaboration the significant XX cornerstone our XX to BMS, earn next over and engagers. Amgen we've date, be $XX collaboration collaborations, Moderna commercial include across focused months including masked research our
first Financial cover me to let over to promotion Chief to Chris on Before congratulate handing financials, his him Officer.
look We cross-functional role. update strategic to excited an our And the and build provide continuing value partner Chris inside this hand to to I over colleagues forward long to leadership and in really as Chris' Chris have over me near we financial experience with term.
With finances. and that, CytomX my on to are key let
